Novel co-crystal of enavogliflozin.

Abstract

The present invention relates to a co-crystal of enavogliflozin. The enavogliflozin co-crystal of the present invention enhances the solubility of enavogliflozin in artificial gastric fluid and artificial intestinal fluid. This improved solubility of enavogliflozin may be particularly advantageous for the development of oral formulations for indications requiring high-dose administration. The enavogliflozin co-crystal also exhibits stability equivalent to that of existing crystalline forms of enavogliflozin, making it highly valuable as an active pharmaceutical ingredient of enavogliflozin. Furthermore, the co-crystal of the present invention has a longer half-life and higher in vivo exposure (AUCinf) compared to the existing crystalline form A, resulting in prolonged efficacy, and thus can be usefully employed in the development of various indications and / or formulations requiring such properties